Leonardo Pazarin-Villaseñor

Dr. Leonardo Pazarin-Villaseñor

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2016 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
ADAlejandra Guillrmina Miranda Díaz
Alejandra Guillrmina Miranda Díaz
LPLeonardo Pazarin-Villaseñor
Leonardo Pazarin-Villaseñor
FEFrancisco Gerardo Yanowsky Escatell
Francisco Gerardo Yanowsky Escatell
Jorge Andrade SierraJorge Andrade Sierra
Jorge Andrade Sierra
The increase in the prevalence of diabetes mellitus (DM) and the secondary kidney damage produces diabetic nephropathy (DN). Early nephropathy is defined as the presence of microalbuminuria (30–300 mg/day), including normal glomerular filtration rate (GFR) or a mildly decreased GFR (60–89 mL/min/1.73 m2), with or without overt nephropathy. The earliest change caused by DN is hyperfiltration with proteinuria. The acceptable excretion rate of albumin in urine is 300 mg/day. Chronic kidney disease (CKD) is characterized by abnormalities in renal function that persist for >3 months with health implications. Alterations in the redox state in DN are caused by the persistent state of hyperglycemia and the increase in advanced glycation end products (AGEs) with ability to affect the renin-angiotensin system and the transforming growth factor-beta (TGF-β), producing chronic inflammation and glomerular and tubular hypertrophy and favoring the appearance of oxidative stress. In DN imbalance between prooxidant/antioxidant processes exists with an increase in reactive oxygen species (ROS). The overproduction of ROS diminishes expression of the antioxidant enzymes (manganese superoxide dismutase, glutathione peroxidase, and catalase). The early detection of CKD secondary to DN and the timely identification of patients would permit decreasing its impact on health.

1 March 2012 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Closed access
PDF file
FCFabiola Martin Del Campo
Fabiola Martin Del Campo
CBCarolina Batis
Carolina Batis
LGLiliana González–Espinoza
Liliana González–Espinoza
EREnrique Rojas–Campos
Enrique Rojas–Campos
JÁJuan R. Ángel
Juan R. Ángel
ACAlfonso Martin Cueto-Manzano
Alfonso Martin Cueto-Manzano
♦ Objective: To compare dietary intake of micronutrients by peritoneal dialysis (PD) patients according to their nutrition and inflammatory statuses.

Verified
Journal Article
Open access
PDF file
TCTannia Isabel Campos Campos-Bayardo
Tannia Isabel Campos Campos-Bayardo
Daniel Roman RojasDaniel Roman Rojas
Daniel Roman Rojas
AGAndrés García-Sánchez
Andrés García-Sánchez
EMErnesto German GERMAN Cardona Muñoz
Ernesto German GERMAN Cardona Muñoz
DSDaniela Itzel Sánchez-Lozano
Daniela Itzel Sánchez-Lozano
ADAlejandra Guillrmina Miranda Díaz
Alejandra Guillrmina Miranda Díaz
Obesity affects the adaptability of adipose tissue (AT), impairing its ability to regulate energy and metabolism. Obesity is associated with many metabolic disorders, including dyslipidemia, hypertension, sleep disorders, non-alcoholic liver disease, and some types of cancer. Toll-like receptors (TLRs) are important in obesity and related metabolic disorders. TLRs are pattern-recognizing receptors (PRRs) involved in the innate immune system and recognize pathogen-associated molecular patterns (PAMPs) and endogenous ligands. TLRs, especially TLR2 and TLR4, are activated by fatty acids, endotoxins, and other ligands. TLR2 and TLR4 activation triggers inflammatory responses. Chronic inflammation driven by TLR activation is a hallmark of obesity and metabolic diseases. The inflammatory response triggered by TLR activation alters insulin signaling, contributing to insulin resistance, a key feature of metabolic syndrome and type 2 diabetes. Modulation of TLR activity through lifestyle changes (diet and exercise), obesity surgery, and pharmacological agents is under study as a possible therapeutic approach to controlling obesity and its complications.

1 November 2013 in Archives of Medical Research
Verified
Journal Article
Closed access
LCLaura Cortés-Sanabria
Laura Cortés-Sanabria
CPCarlos A. Paredes-Ceseña
Carlos A. Paredes-Ceseña
RHRebeca M. Herrera-Llamas
Rebeca M. Herrera-Llamas
YCYolanda Cruz-Bueno
Yolanda Cruz-Bueno
HSHerman Soto-Molina
Herman Soto-Molina
HMHéctor R. Martínez-Ramírez
Héctor R. Martínez-Ramírez

23 July 2009 in Nephrology
Verified
Journal Article
Closed access
PDF file
FCFabiola Martin Del Campo
Fabiola Martin Del Campo
LGLiliana González‐Espinoza
Liliana González‐Espinoza
EREnrique Rojas‐Campos
Enrique Rojas‐Campos
NRNorma Ruiz
Norma Ruiz
JGJuana González
Juana González
ACAlfonso Martin Cueto-Manzano
Alfonso Martin Cueto-Manzano

1 November 2013 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Open access
PDF file
LCLaura Cortés–Sanabria
Laura Cortés–Sanabria
BRBrenda E. Rodríguez–Arreola
Brenda E. Rodríguez–Arreola
VOVictor R. Ortiz–Juárez
Victor R. Ortiz–Juárez
HSHerman Soto–Molina
Herman Soto–Molina
LPLeonardo Pazarin-Villaseñor
Leonardo Pazarin-Villaseñor
ACAlfonso Martin Cueto-Manzano
Alfonso Martin Cueto-Manzano
♦ Objective: We set out to estimate the direct medical costs (DMCs) of peritoneal dialysis (PD) and to compare the DMCs for continuous ambulatory PD (CAPD) and automated PD (APD). In addition, DMCs according to age, sex, and the presence of peritonitis were evaluated.